[go: up one dir, main page]

CL2018001705A1 - Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante. - Google Patents

Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante.

Info

Publication number
CL2018001705A1
CL2018001705A1 CL2018001705A CL2018001705A CL2018001705A1 CL 2018001705 A1 CL2018001705 A1 CL 2018001705A1 CL 2018001705 A CL2018001705 A CL 2018001705A CL 2018001705 A CL2018001705 A CL 2018001705A CL 2018001705 A1 CL2018001705 A1 CL 2018001705A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
antioxidant
composition
amorphous lenalidomide
pharmaceutically acceptable
Prior art date
Application number
CL2018001705A
Other languages
English (en)
Inventor
Martinez Marta Vivancos
Fernandez Lisardo Alvarez
Calzada Jose Velada
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of CL2018001705A1 publication Critical patent/CL2018001705A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE LENALIDOMIDA AMORFA, O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES, CON UN ANTIOXIDANTE SINTÉTICO Y UNO O MÁS EXCIPIENTES FARMACÉUTICAMENTE ACEPTABLES. LA INVENCIÓN SE RELACIONA ADEMÁS CON UN PROCESO DE FABRICACIÓN DE DICHA COMPOSICIÓN Y EL USO DE DICHA COMPOSICIÓN COMO MEDICAMENTO, ESPECIALMENTE EN EL TRATAMIENTO DE MIELOMA MÚLTIPLE Y SÍNDROMES MIELODIPLÁSICOS.
CL2018001705A 2015-12-22 2018-06-21 Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante. CL2018001705A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15202069 2015-12-22

Publications (1)

Publication Number Publication Date
CL2018001705A1 true CL2018001705A1 (es) 2018-08-10

Family

ID=55068830

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001705A CL2018001705A1 (es) 2015-12-22 2018-06-21 Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante.

Country Status (7)

Country Link
US (2) US10328028B2 (es)
EP (1) EP3393457A1 (es)
AU (1) AU2016378482A1 (es)
CL (1) CL2018001705A1 (es)
EA (1) EA036205B1 (es)
MX (1) MX385876B (es)
WO (1) WO2017109041A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016097030A1 (en) * 2014-12-19 2016-06-23 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060680T2 (hu) 2015-11-19 2023-04-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
EP3394033B1 (en) 2015-12-22 2020-11-25 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
TW201808902A (zh) 2016-05-26 2018-03-16 美商英塞特公司 作為免疫調節劑之雜環化合物
MD3472167T2 (ro) 2016-06-20 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
WO2018013693A1 (en) * 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
MA47123A (fr) 2016-12-22 2021-03-17 Incyte Corp Dérivés de benzooxazole en tant qu'mmunomodulateurs
PE20200005A1 (es) 2016-12-22 2020-01-06 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
RU2020110236A (ru) 2017-10-26 2021-11-26 Синбиас Фарма АГ Состав леналидомида с немедленным высвобождением
US11452722B2 (en) 2018-01-11 2022-09-27 Natco Pharma Limited Stable pharmaceutical compositions comprising lenalidomide
PL4212529T3 (pl) 2018-03-30 2025-07-07 Incyte Corporation Związki heterocykliczne jako immunomodulatory
WO2019199136A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 붕해가 개선된 레날리도마이드의 경구용 정제 조성물
HRP20230306T1 (hr) 2018-05-11 2023-05-12 Incyte Corporation Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori
KR20220003552A (ko) * 2019-04-22 2022-01-10 스타트온 테라퓨틱스, 인크. 레날리도미드 및 다른 면역조정제의 연속적 전달
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
IL291471B2 (en) 2019-09-30 2025-04-01 Incyte Corp Pyrimido[3,2–D]pyrimidine compounds as immunomodulators
CR20220237A (es) 2019-11-11 2022-08-05 Incyte Corp Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
CN110664761A (zh) * 2019-11-18 2020-01-10 杭州百诚医药科技股份有限公司 一种来那度胺药物组合物及其制备方法
AR124001A1 (es) 2020-11-06 2023-02-01 Incyte Corp Proceso para fabricar un inhibidor pd-1 / pd-l1 y sales y formas cristalinas del mismo
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
CA3204385A1 (en) 2021-01-08 2022-07-14 Rod L. Hartwig Stable solutions of immunomodulatory imide compounds for parenteral use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL195916B1 (pl) 1996-07-24 2007-11-30 Celgene Corp Izomery optyczne podstawionej 1-okso-izoindoliny i 1,3-diokso-izoindoliny, kompozycje farmaceutyczne je zawierające oraz ich zastosowanie
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
AU2009223014A1 (en) 2008-03-11 2009-09-17 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
JP2012507496A (ja) 2008-11-03 2012-03-29 ジェネリクス・（ユーケー）・リミテッド レナリドマイドの結晶形およびその調製方法
WO2010054833A1 (de) * 2008-11-14 2010-05-20 Ratiopharm Gmbh Intermediate und orale darreichungsformen enthaltend lenalidomid
PT2403845E (pt) * 2009-03-02 2014-08-04 Generics Uk Ltd Processo melhorado
CN101537184B (zh) * 2009-04-30 2011-04-20 杭州中美华东制药有限公司 一种含水难溶高活性药物的组合物及其制备方法
WO2011111053A1 (en) 2010-03-08 2011-09-15 Natco Pharma Limited Anhydrous lenalidomide form-i
US20150126582A1 (en) * 2012-04-30 2015-05-07 Sevion Therapeutics, Inc. Combination Treatment of Multiple Myeloma
US9808450B2 (en) * 2013-03-26 2017-11-07 Celgene Corporation Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
CN103705485B (zh) * 2013-12-31 2015-07-22 广州帝奇医药技术有限公司 一种用于治疗骨髓增生异常综合症的组合物及其制备方法

Also Published As

Publication number Publication date
EA036205B1 (ru) 2020-10-14
MX2018007704A (es) 2018-11-09
EP3393457A1 (en) 2018-10-31
WO2017109041A1 (en) 2017-06-29
MX385876B (es) 2025-03-18
AU2016378482A1 (en) 2018-07-12
US11007152B2 (en) 2021-05-18
US20190240157A1 (en) 2019-08-08
EA201891489A1 (ru) 2018-11-30
US10328028B2 (en) 2019-06-25
US20180256501A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
CL2018001705A1 (es) Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
DOP2017000048A (es) Compuestos aminopirimidinilo como inhibidores de jak.
GEP20217239B (en) Pharmaceutical composition
CL2016001933A1 (es) Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct
SV2017005419A (es) Triazolopirazinonas como inhibidores de pde1
CL2016002971A1 (es) Combinación.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX2017001512A (es) Compuestos activos hacia bromodominios.
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
GT201700223A (es) Imidazopirazinonas como inhibidores de pde 1
CL2015002897A1 (es) Inhibidores de bace1
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
CO2017002472A2 (es) Formulación de acetato de abiraterona
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
EP3197498C0 (en) COMPOSITIONS CONTAINING INACTIVATED BUT THERAPEUTICALLY ACTIVE BIOPHARMACEUTICALS, STABLE AT ROOM TEMPERATURE AND ASSOCIATED FORMULATION METHODS
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
GEP20217240B (en) Pharmaceutical composition
BR112017000730B8 (pt) Derivados de pirrolidinona como inibidores de metap-2, e medicamentos
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio